Tesamorelin

TL;DR

Tesamorelin is an FDA-approved synthetic GHRH analog (44 AA, N-terminal trans-3-hexenoic acid modification for DPP-IV resistance) that stimulates physiological pulsatile GH release to selectively reduce visceral fat 15–18%, improve liver health, and enhance cognitive function — without the insulin resistance or tachyphylaxis of exogenous rhGH. The gold standard for somatotropic axis modulation with robust Phase III RCT data. Off-label use in longevity medicine is growing. Must be dosed in the evening, fasted.

---

Key Facts

Status	FDA approved (HIV lipodystrophy — Egrifta Nov 2010; Egrifta WR F8 March 2025) · Off-label anti-aging/longevity
Class	Synthetic GHRH analog · 44 amino acids · DPP-IV resistant modification
Mechanism	GHRH-R activation → pulsatile GH → visceral fat lipolysis (HSL) + hepatic IGF-1 (JAK2/STAT5)
Half-life	26–38 min (subQ); IGF-1 elevation sustained
Key benefits	VAT reduction 15–18% / ~24–34 cm² over 26 wks; hepatic fat −37%; cognitive improvement in MCI populations
Dosing	1–2 mg/day SubQ · Evening · Fasted (≥2–3 hr post-prandial) · 3–6 months on / 1–2 months off
Main risks	Injection site reactions; fluid retention (edema, arthralgia, carpal tunnel); transient early insulin resistance; ~50% antibody formation (mostly non-neutralizing)
Evidence	Multiple Phase III RCTs (816 HIV patients); Phase II cognitive RCTs; ongoing trials in frailty/NAFLD/nerve regeneration

---

Mechanism of Action

GHRH Receptor Activation

1. Binding: Tesamorelin (trans-3-hexenoic acid-modified GHRH) binds GHRH-R on pituitary somatotrophs
2. cAMP/PKA/CREB pathway: → GH gene transcription ↑↑ + vesicular GH packaging
3. PLC/IP3/Ca²⁺ pathway: → acute GH exocytosis

The key advantage: GHRH-R activation → purely pulsatile GH release → preserves natural feedback loops, prevents tachyphylaxis, maintains receptor sensitivity.

Why Visceral Fat Specifically?

Visceral adipocytes express substantially higher GH receptor density vs. subcutaneous adipocytes. GH binding → HSL phosphorylation + LPL inhibition → selective visceral lipolysis that spares subcutaneous fat.

IGF-1 and Glucose

• GH → liver JAK2/STAT5 → IGF-1 synthesis
• Initial (week 2): mild fasting glucose increase (~9 mg/dL above placebo)
• Long-term: VAT clearance offsets diabetogenic effect → glucose-neutral over 26–52 weeks
• Dedicated T2D trial (12 wks): no significant HbA1c or insulin impact vs. placebo

Cognitive Effects

GHRH crosses BBB → hippocampal/cortical GHRH-R activation:

• ↑ GABA and NAAG in prefrontal cortex
• ↓ myo-inositol (glial inflammation marker — early AD correlate)
• Baker et al. 2012 (MCI, n=152): significant executive function + verbal memory improvement
• HIV NCI cohort (CROI 2024): trend but not statistically significant vs. SOC — viral neuroinflammation more recalcitrant

---

Clinical Evidence Summary

Domain	Metric	Result
Visceral fat	VAT reduction at 26 wks	−15.4% to −18% (−24 to −34 cm²) · P<0.001
Muscle quality	CT muscle density (HU)	+1.56 to +4.86 HU (less myosteatosis) · P<0.005
Hepatic fat	MRS hepatic fat fraction	−37% relative; 35% resolved NAFLD · P=0.02
Liver fibrosis	Biopsy progression	10.5% tesamorelin vs. 37.5% placebo · P=0.04
Triglycerides	Circulating TG	−0.6 to −0.8 mmol/L · P≤0.005
Cognition (MCI)	Executive function	Stroop/Task Switching improvement · P=0.005
Cardiovascular	Carotid IMT	No significant regression at 6 months

---

Wearable Biometric Effects

Biomarker	Expected Effect	Rationale
HRV	↑ Overnight RMSSD/SDNN	SWS enhancement → parasympathetic dominance
RHR	↓ Slight decrease	Vagal tone elevation from deeper SWS
Sleep fragmentation	↓ Reduced WASO	GHRH consolidates NREM sleep stages
Recovery scores	↑ Upward trend	Aggregate of SWS + HRV + RHR improvement

Caution: In RED-S or severe caloric restriction, high HRV + low RHR can reflect metabolic conservation, not true recovery. Ensure adequate nutrition during tesamorelin use.

---

Safety

Risk	Detail
Fluid retention	RAAS upregulation → peripheral edema, arthralgia, carpal tunnel; transient
Glucose	Early mild insulin resistance (transient); long-term glucose-neutral; monitor HbA1c
Antibodies	~50% form anti-tesamorelin IgG; overwhelmingly non-neutralizing; <5–10% true neutralizing
Oncogenic (theoretical)	IGF-1 is a broad mitogen. FDA label contraindicates active malignancy. Discontinue if IGF-1 >+3 SDS.
Discontinuation rebound	IGF-1 returns to baseline within weeks; VAT reaccumulates rapidly — not a cure

---

Key Stacks

Stack	Rationale
+ CJC-1295 Ipamorelin	Tesamorelin (GHRH axis) + Ipamorelin (GHSR axis) = dual neuroendocrine GH stimulation; larger, more robust pulses than either alone
+ GHK-Cu	GH-mediated lipolysis increases cellular turnover; GHK-Cu ensures ECM quality and provides copper for antioxidant defense
+ Retatrutide	Retatrutide drives caloric deficit; tesamorelin preserves lean mass and targets visceral fat specifically

---

Dosing Summary

Parameter	Value
Route	SubQ daily (abdomen, rotate)
Dose	1–2 mg/day (F8: 1.28 mg)
Timing	Evening, 30–60 min before bed, fasted
Cycle	3–6 months on → 1–2 months off
Reconstituted shelf life	21 days (shorter than most — track carefully)

---

Links

• Peptides MOC
• CJC-1295 Ipamorelin — synergistic stack partner
• GHK-Cu — tissue quality companion
• Retatrutide — complementary visceral fat targeting
• Epithalon — NAD+ synergy + sleep axis complement
• HRV signatures — wearable biometric context